Say what you will about the $158,000 price tag on Amylyx’s newly minted Relyvrio or the worthiness of the CENTAUR trial, the FDA’s approval of its third-ever ALS drug has ignited the growing momentum in the space.
https://www.pharmalive.com/wp-content/uploads/2022/10/BioSpaceAmylyx10-3-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-03 09:30:142022-10-03 11:17:17Amylyx and ALS researchers look to build on Relyvrio momentum